TWI603971B - Novel quinoline substituted compounds - Google Patents

Novel quinoline substituted compounds Download PDF

Info

Publication number
TWI603971B
TWI603971B TW103129036A TW103129036A TWI603971B TW I603971 B TWI603971 B TW I603971B TW 103129036 A TW103129036 A TW 103129036A TW 103129036 A TW103129036 A TW 103129036A TW I603971 B TWI603971 B TW I603971B
Authority
TW
Taiwan
Prior art keywords
amino
quinolin
formula
compound
group
Prior art date
Application number
TW103129036A
Other languages
English (en)
Chinese (zh)
Other versions
TW201542547A (zh
Inventor
Takao Uno
Katsumasa Nonoshita
Tadashi Shimamura
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of TW201542547A publication Critical patent/TW201542547A/zh
Application granted granted Critical
Publication of TWI603971B publication Critical patent/TWI603971B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
TW103129036A 2013-08-22 2014-08-22 Novel quinoline substituted compounds TWI603971B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013172746 2013-08-22

Publications (2)

Publication Number Publication Date
TW201542547A TW201542547A (zh) 2015-11-16
TWI603971B true TWI603971B (zh) 2017-11-01

Family

ID=52483707

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103129036A TWI603971B (zh) 2013-08-22 2014-08-22 Novel quinoline substituted compounds

Country Status (21)

Country Link
US (2) US9650386B2 (cg-RX-API-DMAC7.html)
EP (1) EP3037424B1 (cg-RX-API-DMAC7.html)
JP (1) JP6161705B2 (cg-RX-API-DMAC7.html)
KR (1) KR101906688B1 (cg-RX-API-DMAC7.html)
CN (1) CN105683195B (cg-RX-API-DMAC7.html)
AU (1) AU2014309788B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016003247B1 (cg-RX-API-DMAC7.html)
CA (1) CA2922077C (cg-RX-API-DMAC7.html)
DK (1) DK3037424T3 (cg-RX-API-DMAC7.html)
ES (1) ES2656712T3 (cg-RX-API-DMAC7.html)
HU (1) HUE034807T2 (cg-RX-API-DMAC7.html)
MX (1) MX370808B (cg-RX-API-DMAC7.html)
MY (1) MY182891A (cg-RX-API-DMAC7.html)
NO (1) NO3037424T3 (cg-RX-API-DMAC7.html)
PH (1) PH12016500225B1 (cg-RX-API-DMAC7.html)
PL (1) PL3037424T3 (cg-RX-API-DMAC7.html)
PT (1) PT3037424T (cg-RX-API-DMAC7.html)
RU (1) RU2689158C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201600759XA (cg-RX-API-DMAC7.html)
TW (1) TWI603971B (cg-RX-API-DMAC7.html)
WO (1) WO2015025936A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI603971B (zh) * 2013-08-22 2017-11-01 Taiho Pharmaceutical Co Ltd Novel quinoline substituted compounds
AU2017350440B2 (en) * 2016-10-31 2023-01-12 Taiho Pharmaceutical Co., Ltd. Selective inhibitor of exon 20 insertion mutant EGFR
BR112019010020A2 (pt) * 2016-11-17 2019-08-20 Univ Texas compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
FR3068971B1 (fr) * 2017-07-12 2019-08-30 Protneteomix Acides 5-{4-allyl-5-[2-(4-alcoxyphenyl)quinolein-4-yl]-4h-1,2,4-triazole-3-ylsulphanylmethyl}furan-2-carboxyliques dans le traitement du cancer
FI3677266T3 (fi) * 2017-09-01 2024-03-22 Taiho Pharmaceutical Co Ltd Eksoni 18- ja/tai eksoni 21 -egfr-mutantille selektiivinen inhibiittori
CN113423403B (zh) * 2018-12-28 2025-02-18 大鹏药品工业株式会社 对l718和/或l792突变型治疗有抗性的egfr抑制剂
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
JP7109013B2 (ja) 2019-03-19 2022-07-29 ボロノイ インコーポレイテッド ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物
US12629375B2 (en) 2019-03-29 2026-05-19 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions
WO2021057796A1 (zh) * 2019-09-29 2021-04-01 深圳市塔吉瑞生物医药有限公司 取代的稠合三环衍生物及其组合物及用途
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
CN113861195B (zh) * 2020-06-30 2022-11-18 上海和誉生物医药科技有限公司 一种多稠环egfr抑制剂及其制备方法和应用
CN116096372B (zh) * 2020-07-09 2024-09-03 上海和誉生物医药科技有限公司 一种egfr抑制剂、其制备方法和在药学上的应用
US20230372346A1 (en) * 2020-09-08 2023-11-23 Cullinan Pearl Corp. Treatment regimens for exon-20 insertion mutant egfr cancers
WO2022121967A1 (zh) * 2020-12-09 2022-06-16 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
JP2024523861A (ja) * 2021-06-15 2024-07-02 ジェネンテック, インコーポレイテッド がんを処置するための併用療法におけるegfr阻害剤およびperk活性化剤、ならびにこれらの使用
CN115707704B (zh) * 2021-08-20 2024-09-13 广东医诺维申生物技术有限公司 氘代稠合三环类化合物及其组合物和用途
CN120641417A (zh) * 2022-12-08 2025-09-12 亚细亚化学工业有限公司 齐帕勒替尼的固态形式及其制备方法
CN115785107B (zh) * 2022-12-15 2024-11-12 南京雷正医药科技有限公司 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途
EP4722218A1 (en) * 2023-05-31 2026-04-08 Taiho Pharmaceutical Co., Ltd. Crystal of quinoline-substituted compound
CN122206681A (zh) 2023-12-27 2026-06-12 阿西亚化学工业有限公司 Zipalertinib盐酸盐的固态形式及其制备工艺
WO2025167588A1 (zh) * 2024-02-05 2025-08-14 苏州科睿思制药有限公司 Zipalertinib的晶型及其制备方法和用途
WO2026095022A1 (ja) * 2024-11-01 2026-05-07 大鵬薬品工業株式会社 キノリン置換化合物の結晶

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW440562B (en) 1994-05-20 2001-06-16 Taiho Pharmaceutical Co Ltd Condensed-indan derivative and pharmaceutically acceptable salts thereof
WO2006102079A1 (en) 2005-03-17 2006-09-28 Novartis Ag N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
SG177306A1 (en) 2009-07-10 2012-02-28 Taiho Pharmaceutical Co Ltd Azabicyclo compound and salt thereof
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
CA2824013A1 (en) 2011-01-07 2012-07-12 Taiho Pharmaceutical Co., Ltd. Novel bicyclic compound or salt thereof
WO2013047813A1 (ja) * 2011-09-30 2013-04-04 大鵬薬品工業株式会社 1,2,4-トリアジン-6-カルボキサミド誘導体
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
TW201336847A (zh) 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd 喹啉基吡咯并嘧啶化合物或其鹽
US8889666B2 (en) 2012-02-23 2014-11-18 Taiho Pharmaceutical Co., Ltd. Quinolyl pyrrolo pyrimidyl condensed-ring compound and salt thereof
KR20150119401A (ko) * 2013-02-22 2015-10-23 다이호야쿠힌고교 가부시키가이샤 3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물
TWI603971B (zh) * 2013-08-22 2017-11-01 Taiho Pharmaceutical Co Ltd Novel quinoline substituted compounds

Also Published As

Publication number Publication date
JP6161705B2 (ja) 2017-07-12
SG11201600759XA (en) 2016-03-30
US20170101414A1 (en) 2017-04-13
HK1222393A1 (zh) 2017-06-30
RU2019114688A (ru) 2020-07-29
PH12016500225A1 (en) 2016-05-02
PT3037424T (pt) 2017-12-18
US9650386B2 (en) 2017-05-16
KR20160043114A (ko) 2016-04-20
BR112016003247B1 (pt) 2022-05-10
MX370808B (es) 2020-01-07
EP3037424B1 (en) 2017-11-08
ES2656712T3 (es) 2018-02-28
HUE034807T2 (en) 2018-02-28
MY182891A (en) 2021-02-05
CA2922077A1 (en) 2015-02-26
MX2016002125A (es) 2016-06-28
US20160194332A1 (en) 2016-07-07
AU2014309788B2 (en) 2017-02-16
RU2016110096A (ru) 2017-09-27
NO3037424T3 (cg-RX-API-DMAC7.html) 2018-04-07
BR112016003247A2 (cg-RX-API-DMAC7.html) 2017-08-01
EP3037424A1 (en) 2016-06-29
RU2689158C2 (ru) 2019-05-24
KR101906688B1 (ko) 2018-10-10
AU2014309788A1 (en) 2016-03-10
CN105683195A (zh) 2016-06-15
TW201542547A (zh) 2015-11-16
PL3037424T3 (pl) 2018-03-30
CN105683195B (zh) 2017-11-10
DK3037424T3 (en) 2017-12-11
PH12016500225B1 (en) 2016-05-02
EP3037424A4 (en) 2017-01-25
JPWO2015025936A1 (ja) 2017-03-02
WO2015025936A1 (ja) 2015-02-26
RU2016110096A3 (cg-RX-API-DMAC7.html) 2018-06-18
CA2922077C (en) 2018-06-26
US9758526B2 (en) 2017-09-12

Similar Documents

Publication Publication Date Title
JP6161705B2 (ja) 新規キノリン置換化合物
TWI496783B (zh) Quinolylpyrrolopyrimidine condensed cyclic compounds or salts thereof
TW201336847A (zh) 喹啉基吡咯并嘧啶化合物或其鹽
TW201619150A (zh) 用於調節egfr突變型激酶活性的化合物及組成物
JP5415403B2 (ja) 9−(ピラゾール−3−イル)−9h−プリン−2−アミンおよび3−(ピラゾール−3−イル)−3h−イミダゾ[4,5−b]ピリジン−5−アミン誘導体および癌の処置のためのそれらの使用
RU2797117C2 (ru) Новое хинолин-замещенное соединение
HK1222393B (en) Quinoline-substituted compound
HK1202862B (en) Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof